Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Ambien (zolpidem tartrate) dose, indications, adverse effects


Udocheals.orgZolpidem tartrate
8.10.2017 | Logan Miers
Zolpidem tartrate
Ambien (zolpidem tartrate) dose, indications, adverse effects

Not a Member? Register Now this page.

Send the page " " to a friend, relative, colleague or yourself.

Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness. Use only if the patient has at least 4 hours of bedtime remaining before the planned time of waking. 3.5 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. A lower dose of 1.75 mg sublingually is recommended for males patients taking other CNS depressants. Avoid co-use with other sedative-hypnotics, including other zolpidem products, at bedtime or in the middle of the night.

During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. All sleep medications should be used in accordance with approved product labeling. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. 5 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Use the lowest effective dose. Administer as a single dose and do not be re-administer during the same night. In residents meeting the criteria for treatment, Max: 5 mg/day PO in residents meeting the criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug.

Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist.

Max: 12.5 mg/day PO at bedtime if needed; however, the higher dose is more likely to cause next-day impairment. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Initially, 6.25 to 12.5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. A dose of 6.25 mg PO before bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. Avoid co-use with other sedative-hypnotics, including other zolpidem products. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. The recommended dose for debilitated adults is 6.25 mg immediay before bedtime; these patients may be particularly sensitive to the effects of the drug. Zolpidem should be taken as a single dose and should not be re-administered during the same night.

Avoid co-use with other sedative-hypnotics, including other zolpidem products at bedtime or in the middle of the night. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. The 1.75 mg dose is also recommended for patients receiving a concomitant CNS depressant. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. 1.75 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep. Daily dose thresholds are not available for zolpidem use in middle-of-the night awakenings; use in accordance with approved product labeling. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. Use only when there are at least 4 hours of bedtime remaining before the planned time of waking. Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness.

Administer as a single dose and do not re-administer during the same night. Initially, 5 to 10 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg PO immediay before bedtime is the final dose recommended for debilitated adults. 5 mg PO at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Avoid co-use with other sedative-hypnotics, including other zolpidem products. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Use the lowest effective dose.

Initially, 6.25 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. The recommended dose for debilitated adults is 6.25 mg immediay before bedtime; these patients may be particularly sensitive to the effects of the drug. Max: 12.5 mg/day PO at bedtime if needed; however, the higher dose is more likely to cause next-day impairment. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Avoid co-use with other sedative-hypnotics, including other zolpidem products. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Zolpidem should be taken as a single dose and should not be re-administered during the same night.

The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug. 6.25 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. Patients should be cautioned regarding the risk of residual next-morning effects, and warned against engaging in hazardous activities, such as driving or other activities requiring complete mental alertness, the day after use until the patient is aware of how zolpidem affect them. Max: 6.25 mg/day PO in residents meeting criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. All sleep medications should be used in accordance with approved product labeling. Zolpidem should be taken as a single dose and should not be re-administered during the same night. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. Avoid co-use with other sedative-hypnotics, including other zolpidem products. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects.

Use the lowest effective dose. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Administer as a single dose and do not re-administer during the same night. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Initially, 5 mg PO (1 spray in mouth over the tonque) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment.

1.75 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep. The 1.75 mg dose is also recommended for patients receiving a concomitant CNS depressant. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. Avoid co-use with other sedative-hypnotics, including other zolpidem products at bedtime or in the middle of the night. Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness. Use only if the patient has at least 4 hours of bedtime remaining before the planned time of waking.

Use the lowest effective dose. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Initially, 5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Administer as a single dose and do not re-administer during the same night. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment.

Avoid co-use with other sedative-hypnotics, including other zolpidem products. Administer as a single dose and do not re-administer during the same night. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Initially, 5 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults. Use the lowest effective dose. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment.

Non-benzodiazepine hypnotic. Available in immediate and extended release formulations; rapid onset and short half-life reduces 'hangover' effects; does not cause early-AM awakening. Used for insomnia to aide in sleep initiation; some products may be used for middle-of-the night awakenings.

We do not record any personal information entered above.

A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Avoid co-use with other sedative-hypnotics, including other zolpidem products. 5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents.Max: 5 mg/day PO in residents meeting the criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. Use the lowest effective dose. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. Administer as a single dose and do not re-administer during the same night. All sleep medications should be used in accordance with approved product labeling. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Geriatric patients and debilitated adults are particularly sensitive to the effects of zolpidem.

All sleep medications should be used in accordance with approved product labeling. Avoid co-use with other sedative-hypnotics, including other zolpidem products. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug. Max: 5 mg/day PO in residents meeting criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Administer as a single dose and do not be re-administer during the same night. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. 5 mg PO (1 spray into mouth and over the tongue) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. Use the lowest effective dose.

During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. The 5 mg dose is recommended for debilitated adults. Initially, 5 to 10 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg PO at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. Administer as a single dose and do not re-administer during the same night. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Use the lowest effective dose. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Avoid co-use with other sedative-hypnotics, including other zolpidem products.

Separate multiple address with a comma.

Administer as a single dose and do not re-administer during the same night. Initially, 5 to 10 mg PO (1 to 2 sprays in mouth over the tongue) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg (1 spray) at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. Use the lowest effective dose. The 5 mg dose is recommended for debilitated adults. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Avoid co-use with other sedative-hypnotics, including other zolpidem products. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness.

Ambien CR/Zolpidem/Zolpidem Tartrate Oral Tab ER: 6.25mg, 12.5mg Ambien/Zolpidem/Zolpidem Tartrate Oral Tab: 5mg, 10mg Edluar/Intermezzo/Zolpidem/Zolpidem Tartrate Sublingual Tablet, SL: 1.75mg, 3.5mg, 5mg, 10mg Zolpimist Oropharyngeal Spray Met: 1actuation, 5mg.

Thank you. Benzodiazepine Related Sedative/Hypnotics Rx, schedule IV. Your has been sent.

Zolpidem tartrate